Immune checkpoint inhibitors (ICIs), particularly those targeting programmed cell death protein 1 (PD-1), have demonstrated significant efficacy in advanced and metastatic GC, as evidenced by the landmark phase 3 CheckMate 649, KEYNOTE-811, and ORIENT-16 trials (9–11). The gene discussed is PDCD1; the disease is gastric cancer.